Page last updated: 2024-08-16

temozolomide and rucaparib

temozolomide has been researched along with rucaparib in 12 studies

Research

Studies (12)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (33.33)	29.6817
2010's	6 (50.00)	24.3611
2020's	2 (16.67)	2.80

Authors

Authors	Studies
Choi, PJ; Cooper, E; Denny, WA; Dragunow, M; Faull, R; Jose, J; Mee, E; Park, TI; Schweder, P; Turner, C	1
Feng, Y; Gao, Y; Gong, W; Guo, Y; Huo, CX; Jiang, B; Kuang, X; Liu, X; Liu, Y; Luo, L; Lv, L; Peng, H; Qi, R; Qin, Z; Qiu, M; Ren, B; Su, D; Sun, X; Tang, T; Wang, F; Wang, H; Wang, L; Wang, X; Wang, Z; Wei, M; Wu, Y; Xu, D; Xu, H; Yan, H; Yu, F; Zhao, Y; Zhou, C; Zhu, Y	1
Batey, MA; Calabrese, CR; Canan, S; Curtin, NJ; Hostomsky, Z; Kyle, S; Maegley, KA; Newell, DR; Skalitzky, D; Thomas, HD; Wang, LZ; Webber, SE	1
Boddy, A; Calvert, H; Curtin, N; Dewji, R; Evans, J; Harris, A; Johnson, P; Jones, C; McHugh, P; Middleton, M; Newell, D; Olsen, A; Plummer, R; Robson, L; Steinfeldt, H; Wang, D; Wilson, R	1
Boddy, AV; Castelbuono, DJ; Clifford, SC; Curtin, NJ; Daniel, RA; Drew, Y; Hostomsky, Z; Mulligan, EA; Plummer, ER; Rozanska, AL; Thomas, HD; Tweddle, DA	2
Ali, M; Curtin, NJ; Hirst, DG; Kamjoo, M; Kyle, S; McCrudden, C; O'Rourke, M; Robson, T; Shaw, C; Telfer, BA; Thomas, HD; Williams, KJ	1
Abbattista, A; Calvert, H; Curtin, N; Dewji, R; Gallo, J; Lorigan, P; Middleton, MR; Mulligan, E; Plummer, R; Scott, L; Steven, N; Wang, D; Wilson, RH	1
Camaioni, E; Ekblad, T; Macchiarulo, A; Schüler, H	1
Doroshow, JH; Huang, SY; Ji, J; Morris, J; Murai, J; Pommier, Y; Renaud, A; Takeda, S; Teicher, B; Zhang, Y	1
Agar, NY; Boddy, AV; Calligaris, D; Carlson, BL; Cen, L; Curtin, NJ; Elmquist, WF; Kizilbash, S; Mittapalli, RK; Murray, J; Parrish, KE; Sarkaria, JN; Schroeder, MA; Sludden, J	1
de Stanchina, E; Desmeules, P; Gardner, EE; Lok, BH; Ni, A; Poirier, JT; Powell, SN; Rekhtman, N; Riaz, N; Rudin, CM; Schneeberger, VE; Teicher, BA	1

Reviews

1 review(s) available for temozolomide and rucaparib

Article	Year
PARP inhibitors: polypharmacology versus selective inhibition. The FEBS journal, 2013, Volume: 280, Issue:15 Topics: Amino Acid Motifs; Animals; Antineoplastic Agents; Catalytic Domain; Clinical Trials as Topic; Dacarbazine; Humans; Indoles; Models, Molecular; Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide	2013

Trials

2 trial(s) available for temozolomide and rucaparib

Article	Year
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Dec-01, Volume: 14, Issue:23 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Comet Assay; Cytochrome P-450 CYP2D6; Dacarbazine; DNA Breaks; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Temozolomide	2008
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Drug Synergism; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Poly(ADP-ribose) Polymerase Inhibitors; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome; Young Adult	2013

Article

Year

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Dec-01, Volume: 14, Issue:23

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Comet Assay; Cytochrome P-450 CYP2D6; Dacarbazine; DNA Breaks; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Temozolomide

2008

A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.

Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:5

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Drug Synergism; Female; Humans; Indoles; Male; Melanoma; Middle Aged; Poly(ADP-ribose) Polymerase Inhibitors; Skin Neoplasms; Survival Rate; Temozolomide; Treatment Outcome; Young Adult

2013

Other Studies

9 other study(ies) available for temozolomide and rucaparib

Article	Year
PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines. Bioorganic & medicinal chemistry letters, 2020, 07-15, Volume: 30, Issue:14 Topics: Antineoplastic Agents; Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Indoles; Molecular Structure; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Structure-Activity Relationship	2020
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development. Journal of medicinal chemistry, 2020, 12-24, Volume: 63, Issue:24 Topics: Animals; Binding Sites; Carbazoles; Cell Proliferation; Dogs; Female; Fluorenes; Half-Life; Humans; Indoles; Isoenzymes; Mice; Microsomes; Molecular Docking Simulation; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Rats; Structure-Activity Relationship; Xenograft Model Antitumor Assays	2020
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Molecular cancer therapeutics, 2007, Volume: 6, Issue:3 Topics: Animals; Antineoplastic Agents; Benzodiazepines; Cell Line, Tumor; Colorectal Neoplasms; Dacarbazine; DNA Repair; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Gamma Rays; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Maximum Tolerated Dose; Mice; Mice, Nude; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Structure-Activity Relationship; Temozolomide; Topoisomerase I Inhibitors; Topotecan	2007
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-15, Volume: 15, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Enzyme Inhibitors; Humans; Indoles; Mice; Neuroblastoma; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Topotecan; Xenograft Model Antitumor Assays	2009
Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Oct-01, Volume: 15, Issue:19 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azulenes; Benzodiazepines; Blood Vessels; Capillary Permeability; Dacarbazine; Drug Resistance, Neoplasm; Female; HT29 Cells; Humans; Indoles; Mice; Mice, Nude; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2009
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. British journal of cancer, 2010, Nov-09, Volume: 103, Issue:10 Topics: Animals; Antineoplastic Agents, Alkylating; Cell Division; Cell Line, Tumor; Cell Survival; Central Nervous System Neoplasms; Child; Dacarbazine; DNA Mismatch Repair; DNA Repair; Humans; Indoles; Medulloblastoma; Mice; Mice, Nude; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Protein Serine-Threonine Kinases; Temozolomide; Transplantation, Heterologous	2010
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Molecular cancer therapeutics, 2014, Volume: 13, Issue:2 Topics: Adenosine Triphosphate; Animals; Cell Cycle; Cell Line, Tumor; Cell Survival; Dacarbazine; DNA; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fluorescence Polarization; Humans; Immunoblotting; Indoles; Inhibitory Concentration 50; Methyl Methanesulfonate; Molecular Structure; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Stereoisomerism; Temozolomide	2014
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Molecular cancer therapeutics, 2015, Volume: 14, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Central Nervous System; Dacarbazine; Dogs; Glioblastoma; Humans; Indoles; Madin Darby Canine Kidney Cells; Mice; Mice, Knockout; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Xenograft Model Antitumor Assays	2015
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Jan-15, Volume: 23, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cisplatin; Dacarbazine; Drug Synergism; Etoposide; Gene Expression Regulation, Neoplastic; Genomics; Humans; Indoles; Mice; Nuclear Proteins; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Small Cell Lung Carcinoma; Temozolomide; Xenograft Model Antitumor Assays	2017